MedPath

Tretinoin

Generic Name
Tretinoin
Brand Names
Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana
Drug Type
Small Molecule
Chemical Formula
C20H28O2
CAS Number
302-79-4
Unique Ingredient Identifier
5688UTC01R

Overview

Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles and activates nuclear receptors to regulate epithelial cell growth and differentiation. Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.

Background

Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles and activates nuclear receptors to regulate epithelial cell growth and differentiation. Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.

Indication

Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated. Topical tretinoin is also indicated alone or in combination with benzoyl peroxide or clindamycin for the treatment of acne vulgaris. It is also used in prescription and over-the-counter for treating various skin conditions such as melasma, hyperpigmentation, and photoaging alone or in combination with other drugs.

Associated Conditions

  • Acne Vulgaris
  • Alopecia
  • Cornification and dystrophic skin disorders
  • FAB classification M3 Acute promyelocytic leukemia
  • Fine Wrinkles
  • Photodamaged Skin
  • Skin hyperpigmentation
  • Keratinization disorders of the feet
  • Keratinization disorders of the hand
  • Moderate Melasma
  • Mottled hyperpigmentation
  • Severe Melasma
  • Severe, recalcitrant Cystic acne
  • Tactile roughness of facial skin

FDA Approved Products

Retin-A
Manufacturer:Bausch Health US, LLC
Route:TOPICAL
Strength:0.25 mg in 1 g
Approved: 2019/09/02
NDC:0187-5170
Tretinoin
Manufacturer:NuCare Pharmaceuticals,Inc.
Route:TOPICAL
Strength:0.5 mg in 1 g
Approved: 2022/04/25
NDC:68071-2674
Vesanoid
Manufacturer:H2-Pharma, LLC
Route:ORAL
Strength:10 mg in 1 1
Approved: 2023/06/19
NDC:61269-750
NIACINAMIDE 2% / SPIRONOLACTONE 5% / TRETINOIN 0.025%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:0.025 g in 100 g
Approved: 2019/05/03
NDC:72934-1152
DR. THROWERS HYDROTET
Manufacturer:DR. THROWER'S SKINCARE, INC.
Route:TOPICAL
Strength:0.05 g in 100 g
Approved: 2015/05/22
NDC:69299-102

Singapore Approved Products

RETACNYL 0.05 CREAM 0.05%
Manufacturer:LABORATOIRES GALDERMA
Form:CREAM
Strength:0.05%
Online:Yes
Approved: 1995/03/28
Approval:SIN08098P
VESANOID CAPSULE 10 mg
Manufacturer:F HOFFMANN-LA ROCHE LTD (Primary and Secondary Packager), Catalent Germany Eberbach GmbH, CENEXI SAS (Primary and Secondary Packager)
Form:CAPSULE
Strength:10 mg
Online:Yes
Approved: 1995/03/09
Approval:SIN08057P
RETRIEVE CREAM 0.05% w/w
Manufacturer:Milpharma Pty Ltd
Form:CREAM
Strength:0.5 mg/g
Online:Yes
Approved: 2003/07/24
Approval:SIN12368P
STIEVA-A CREAM 0.05%
Manufacturer:THERAPEX, DIVISION DE E-Z-EM CANADA INC., Aspen Pharma Pty Ltd
Form:CREAM
Strength:0.05% w/w
Online:Yes
Approved: 1990/02/23
Approval:SIN03890P
RETACNYL 0.025 CREAM 0.025%
Manufacturer:LABORATOIRES GALDERMA
Form:CREAM
Strength:0.025%
Online:Yes
Approved: 1995/03/28
Approval:SIN08095P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath